Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV) announced its participation in the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The company will showcase its innovative therapeutics targeting life-threatening diseases, particularly its lead product, AVB-500, which aims to inhibit tumor growth through GAS6-AXL signaling pathways.

The presentation will be available for viewing on January 11, 2021, and can be accessed via their investor relations website, with a 90-day archive for replays.

HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the H.C. Wainwright Virtual BioConnect Conference taking place January 11-14, 2021. Aravive’s presentation will be available for viewing on January 11, 2021.

The webcast and audio archive of the presentation will be available at http://ir.aravive.com. An archived replay of the webcast will be available for 90 days following the presentation.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and selected 15 mg/kg as the dose for the Phase 3 trial. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company has initiated and is recruiting for its Phase 1b/2 trial in patients with clear cell renal cell carcinoma. For more information, please visit www.aravive.com.

Contacts:
Media:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
(213) 262-9390

Investors:
Luke Heagle, W2O
lheagle@w2ogroup.com
(910) 726-1372

FAQ

When is Aravive's presentation at the H.C. Wainwright Virtual BioConnect Conference?

Aravive's presentation is scheduled for January 11, 2021.

What is the focus of Aravive's presentation at the conference?

The presentation will focus on Aravive's innovative therapeutics, specifically the lead product AVB-500.

Where can I watch Aravive's conference presentation?

The presentation will be available on Aravive's investor relations website starting January 11, 2021.

What recent trial results does Aravive have for AVB-500?

In a Phase 1b trial for platinum-resistant ovarian cancer, all 5 patients in the 15 mg/kg cohort experienced clinical benefit.

What future trials is Aravive conducting?

Aravive has initiated a Phase 1b/2 trial in patients with clear cell renal cell carcinoma.